RaQualia Pharma Inc
TSE:4579
RaQualia Pharma Inc
TSE:4579
Price:
609 JPY
1.67%
Market Closed
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one
RaQualia Pharma Inc
stock under the Base Case scenario is
372.98
JPY.
Compared to the current market price of 609 JPY,
RaQualia Pharma Inc
is
Overvalued by 39%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
372.98
JPY
Overvaluation 39%
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
RaQualia Pharma Inc Competitors
RaQualia Pharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| JP |
|
RaQualia Pharma Inc
TSE:4579
|
13.2B JPY | 6.9 | -40.7 | -59.9 | -28.7 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
739.2B USD | 20.6 | 120.4 | 59 | 67.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.9 | 47 | 34.4 | 37.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
357.9B USD | 4.2 | 9.3 | 11.5 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.2B USD | 5.4 | 143.2 | 35.7 | 58.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.8B GBP | 4.9 | 37.1 | 174.3 | 278 | |
| CH |
|
Novartis AG
SIX:NOVN
|
183.5B CHF | 4.3 | 13.6 | 9.9 | 16.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
176.4B CHF | 3 | 15.3 | 8.7 | 10.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 2.8 | -507.4 | 12.6 | 20.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
